Triumph Capital Management Grows Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Triumph Capital Management raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 164.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,240 shares of the company’s stock after purchasing an additional 1,392 shares during the quarter. Triumph Capital Management’s holdings in Eli Lilly and Company were worth $1,305,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of LLY. Simon Quick Advisors LLC grew its stake in Eli Lilly and Company by 10.5% in the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock worth $1,706,000 after purchasing an additional 278 shares during the period. Clear Harbor Asset Management LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter worth about $363,000. Terril Brothers Inc. increased its stake in shares of Eli Lilly and Company by 113.2% in the 4th quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock worth $471,000 after acquiring an additional 429 shares in the last quarter. Hartline Investment Corp grew its holdings in Eli Lilly and Company by 1.1% in the fourth quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock worth $12,786,000 after purchasing an additional 248 shares during the period. Finally, Meritage Portfolio Management boosted its position in shares of Eli Lilly and Company by 23.4% in the 4th quarter. Meritage Portfolio Management now owns 6,377 shares of the company’s stock worth $3,717,000 after purchasing an additional 1,208 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Down 0.9 %

LLY stock traded down $6.85 during mid-day trading on Wednesday, reaching $774.25. 1,349,685 shares of the stock traded hands, compared to its average volume of 3,049,779. The stock has a market capitalization of $735.66 billion, a PE ratio of 133.47, a PEG ratio of 1.61 and a beta of 0.34. Eli Lilly and Company has a one year low of $399.26 and a one year high of $800.78. The business has a 50-day moving average price of $761.41 and a two-hundred day moving average price of $669.21. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. During the same quarter in the prior year, the company posted $1.62 EPS. Eli Lilly and Company’s quarterly revenue was up 26.0% on a year-over-year basis. Equities research analysts expect that Eli Lilly and Company will post 12.51 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Citigroup boosted their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price objective (up from $815.00) on shares of Eli Lilly and Company in a report on Tuesday. BMO Capital Markets upped their target price on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a research note on Wednesday. DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a research report on Wednesday, February 21st. Finally, Bank of America lifted their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $742.95.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.